 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12...2324252627282930313233...3940» |
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
SEMAGLUTIDE IS A SAFE AND EFFECTIVE TREATMENT IN PATIENTS AFTER LIVER TRANSPLANTATION WITH POST-TRANSPLANT DIABETES MELLITUS (Room H - White 1) - Aug 28, 2021 - Abstract #ESOT2021ESOT_450;
Semaglutide is safe and effective in the treatment of PTDM in obese patients following OLTx. These findings need to be confirmed in larger studies.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Caneta Ozempic com defeito https://t.co/Fc0LZ6c21G @novonordisk (Twitter) - Aug 27, 2021
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Effect of Semaglutide on body weight in obese children with craniopharyngioma: a preliminary report () - Aug 27, 2021 - Abstract #ESPE2021ESPE_779;
Semaglutide treatment showed encouraging results regarding the loss of weight in children with craniopharyngioma induced obesity. Further randomized studies are necessary, but preliminary results are usually necessary before performing such large studies.
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
New P2 trial: Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Aug 22, 2021
P2, N=672, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, tirzepatide (LY3298176) / Eli Lilly
Clinical, Journal: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. (Pubmed Central) - Aug 22, 2021
P3
In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
#Pharmacists and/or #pharmacy students? What do you know about Ozempic? Can you answer this NAPLEX question of the week? Thanks @blandman19 and @MHEducation for sharing! https://t.co/wFm6avDkYk (Twitter) - Aug 17, 2021
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Dupixent (dupilumab) / Sanofi, Regeneron, Otezla (apremilast) / Amgen
Includes #Humera for arthritis? What other immune meds? #Stellara #dupixent #otezla or diabetes meds like #Ozempic or #rebelsus #insulin antiinflam for heart? (Twitter) - Aug 13, 2021
- | Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Potential kidney protection with liraglutide and semaglutide - exploratory mediation analysis. (Pubmed Central) - Aug 13, 2021
Our results suggest that HbA and systolic BP may moderately mediate kidney benefits of liraglutide and semaglutide, with all other variables having a small to no effect. Potential kidney benefits may be driven by other mediators or potentially by direct mechanisms.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@novonordiskus Tired of trying to call Ozempic customer support for over a week now and callback system not working. Time to file an FDA complain for defective product. (Twitter) - Aug 12, 2021
- ||| efinopegdutide (HM12525A) / Hanmi, Merck (MSD)
Enrollment open: A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) (clinicaltrials.gov) - Aug 11, 2021
P2a, N=130, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Potential kidney benefits may be driven by other mediators or potentially by direct mechanisms. Not yet recruiting --> Recruiting
- |||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity (clinicaltrials.gov) - Aug 10, 2021
P3, N=150, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, tirzepatide (LY3298176) / Eli Lilly
Clinical: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM https://t.co/nbmICJ6uw8 (Twitter) - Aug 7, 2021
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
NAPLEX Question of the Week: All Things Ozempic https://t.co/clnPtUMc4t #accessmedicine (Twitter) - Aug 2, 2021
- ||||||| Mounjaro (tirzepatide) / Eli Lilly
Trial completion, Trial completion date: SURPASS-2: A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (clinicaltrials.gov) - Aug 2, 2021
P3, N=1879, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Feb 2023 --> Feb 2021
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
New P2 trial: Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes (clinicaltrials.gov) - Jul 28, 2021
P2, N=90, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P4 trial: Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB) (clinicaltrials.gov) - Jul 28, 2021
P4, N=42, Not yet recruiting, Sponsor: University of Colorado, Denver
- |||| Lapsoxym (longacting oxyntomodulin) / Hanmi, J&J, Merck (MSD)
New P2 trial: A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease (EUDRACT) - Jul 27, 2021
P2, N=130, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Great job @novonordiskus for getting doctors to prescribe Wegovy and not even making enough for us to order it for any of our patients. 🙄 (Twitter) - Jul 27, 2021
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@novonordisk my doctor ordered Wegovy for me but pharmacy states order keeps going unfilled by you guys? Is it not available in the USA? (Twitter) - Jul 23, 2021
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Pricing: Sorry Oh-Oh-Oh #ozempic looks like my cost has gone up to $75 a month. I'm switching drugs asap. @novonordisk (Twitter) - Jul 22, 2021
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
مساء الخير دكتورة تنصحي في Ozempic أو Saxenda (Twitter) - Jul 21, 2021
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, PYY1875 / Novo Nordisk
New P2 trial, Combination therapy: A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity (clinicaltrials.gov) - Jul 20, 2021
P2, N=114, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||| Firsocostat (GS-0976) / Gilead, cilofexor/firsocostat (GS-9674/GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
New P2 trial: Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jul 20, 2021
P2, N=440, Not yet recruiting, Sponsor: Gilead Sciences
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, HEOR, Real-world evidence, Real-world: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial (clinicaltrials.gov) - Jul 20, 2021
P4, N=1387, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | Trial completion date: Feb 2023 --> Feb 2021 Recruiting --> Active, not recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Phase classification, Trial primary completion date: GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight (clinicaltrials.gov) - Jul 15, 2021
P1, N=96, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting Phase classification: P2 --> P1 | Trial primary completion date: Jun 2025 --> Jan 2025
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: FOCUS: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (clinicaltrials.gov) - Jul 15, 2021
P3, N=1500, Recruiting, Sponsor: Novo Nordisk A/S
Phase classification: P2 --> P1 | Trial primary completion date: Jun 2025 --> Jan 2025 Trial completion date: Aug 2026 --> Feb 2027 | Trial primary completion date: Jul 2026 --> Dec 2026
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Pricing, Reimbursement: A friend just got a prescription of the diabetes medicine, Ozempic® (semaglutide) injection. 3 syringes: $2200. Fully insured, so out of pocket only $150. Here the problem: 1/ High price means new medicines like this are only for well off people with good insurance Thread (Twitter) - Jul 14, 2021
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] The importance of addressing multiple risk markers in type 2 diabetes: results from LEADER and SUSTAIN 6 (Moscow Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_1136;
P3
In patients with T2D, improvements in ≥2 risk markers confers reduced risk of CVD and nephropathy as compared with 0 or 1 improved risk marker. The results stress the importance of multifactorial intervention targeting all risk markers and the benefit of pleiotropic antidiabetic treatments.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Neutrophil-to-lymphocyte ratio predicts cardiovascular events in patients with type 2 diabetes: post hoc analysis of SUSTAIN 6 and PIONEER 6 (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_811;
P3
Baseline NLR predicts MACE, CV death and all-cause death in patients with T2D and high CV risk. NLR is readily accessible from routinely obtained and inexpensive blood counts; it could offer a convenient, clinically useful inflammatory biomarker for CV risk prediction in this population.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Effect of once-weekly semaglutide on insulin use in subjects with type 2 diabetes: a post hoc analysis of SUSTAIN 6 (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_808;
P3
With OW semaglutide, the need for insulin was lower compared with placebo; insulin initiation was less common and insulin elimination more common at end of treatment, and greater reductions in daily insulin dose from baseline were observed. This reduction in insulin use following initiation of semaglutide, while still achieving clinically relevant reductions in HbA1c, may have benefits for patients.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Derived time in glycaemic range with once-weekly semaglutide vs active comparator: post hoc analysis from the SUSTAIN clinical trial programme (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_807;
P3
Consistent with the superior HbA1c reductions seen in the SUSTAIN clinical trials, OW semaglutide was associated with greater improvements in glucose control based on dTIR vs active comparators in subjects with T2D. This likely reflects more effective glycaemic control where both pre- and post-prandial glucose levels are better kept in range by OW semaglutide.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Reduced glycaemic variability with once-weekly semaglutide vs active comparators in post hoc analysis of the SUSTAIN programme (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_806;
P3
As glucose-dependent action of once-weekly semaglutide may translate to reduced glycaemic variability, we compared within-day glycaemic variability of once-weekly semaglutide vs active comparators (sitagliptin, exenatide extended release, insulin glargine, dulaglutide, canagliflozin and liraglutide) in people with type 2 diabetes (T2D).Materials and This post hoc analysis was based on individual subject data in the full analysis set from the on-treatment without rescue medication period in the SUSTAIN 2 (n=1,225), 3 (n=809), 4 (n=1,082), 7 (n=1,199), 8 (n=788) and 10 (n=577) trials... The reduction of within-day glycaemic variability from baseline to end of treatment was significantly greater with once-weekly semaglutide vs all active comparators, providing supporting evidence for the improvement in clinically relevant outcomes with semaglutide treatment for T2D management.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Treatment with once-weekly semaglutide 2.4 mg improves cardiometabolic risk factors in adults with overweight or obesity and type 2 diabetes: STEP 2 post-hoc analysis (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_804;
P3
Overall, in patients with overweight or obesity and type 2 diabetes, semaglutide 2.4 mg improved cardiometabolic risk vs placebo, indicating favourable effects of semaglutide 2.4 mg in addition to body weight loss. Higher weight loss was associated with greater improvements in cardiovascular risk factors.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Semaglutide 2.4 mg improves health-related quality of life in adults with overweight or obesity and type 2 diabetes in the STEP 2 trial (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_803;
P3
Higher weight loss was associated with greater improvements in cardiovascular risk factors. In adults with overweight or obesity and type 2 diabetes, semaglutide 2.4 mg improved both physical and mental health components vs placebo and led to greater proportions of patients with clinically meaningful changes in weight-related quality of life and physical functioning.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Semaglutide 2.4 mg improves patient-reported outcome measures of physical functioning in adults with overweight or obesity and type 2 diabetes in the STEP 2 trial (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_802;
P3
In adults with overweight or obesity and type 2 diabetes, semaglutide 2.4 mg improved both physical and mental health components vs placebo and led to greater proportions of patients with clinically meaningful changes in weight-related quality of life and physical functioning. In adults with overweight or obesity and type 2 diabetes, semaglutide 2.4 mg improved physical function vs placebo and led to greater proportions of patients with clinically meaningful physical function changes in SF-36 and IWQOL-Lite-CT.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Mobile health application as a real-world data resource: self-recorded weight reduction with once-weekly semaglutide (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_737;
One limitation of the study is that the data are collected from a mobile app and are patients’ self-recorded body weight measurements which depend on the patients’ level of engagement with the app. Nonetheless, the findings indicate that mHealth app may assist in generating RWE from a new source of data.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Patients reaching treatment targets with once-weekly semaglutide in real-world practice: pooled analysis of four SURE studies (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_734;
P=N/A
In a pooled analysis of real-world data from SURE Canada, Denmark/Sweden, Switzerland, and UK, over half of patients with T2D initiating semaglutide achieved HbA1c <7% and weight loss ≥3%, by EOS. The proportion of patients achieving glycaemic and weight-loss targets was similar in the overall population and in the subset of patients who had a baseline HbA1c ≥7%.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_733;
P=N/A
The proportion of patients achieving glycaemic and weight-loss targets was similar in the overall population and in the subset of patients who had a baseline HbA1c ≥7%. In a pooled analysis of real-world data from Canada, Denmark/Sweden, Switzerland and the UK, patients with T2D initiating semaglutide experienced significant reductions in HbA1c and body weight, in the overall population and in subgroups based on various BL characteristics, including switching from another GLP-1RA.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Semaglutide reduces hsCRP levels across different treatment settings: post hoc analyses of SUSTAIN and PIONEER trials (Saint Petersburg Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_530;
P3
The observed reductions in hsCRP in subjects with T2D suggest a possible anti-inflammatory effect of semaglutide. Ongoing trials will provide further insights into the impact of semaglutide as an anti-inflammatory drug and its cardiovascular effects.
- Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Efficacy and safety of GLP-1RAs with or without baseline SGLT-2i: post hoc analysis of the SUSTAIN 10 trial (Madrid Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_506;
P3
Our results suggest that addition of a GLP-1RA to SGLT-2i treatment was associated with further reductions from baseline in HbA1c, BW and SBP without additional safety concerns. As SGLT-2is and GLP-1RAs are often used together in clinical practice, our data on the safety and efficacy of combining these two classes are meaningful to clinical decision-making.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, tirzepatide (LY3298176) / Eli Lilly
[VIRTUAL] Efficacy and safety of tirzepatide versus semaglutide once weekly as add-on therapy to metformin in people with type 2 diabetes (SURPASS-2) (Madrid Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_505;
P3
As SGLT-2is and GLP-1RAs are often used together in clinical practice, our data on the safety and efficacy of combining these two classes are meaningful to clinical decision-making. In conclusion, all TZP doses demonstrated superior and clinically meaningful improvement in glycaemic control and substantial weight loss vs once weekly SEMA 1 mg in people with T2D treated with metformin.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Semaglutide reduced cardiovascular events regardless of metformin use: a post hoc exploratory subgroup analysis of SUSTAIN 6 and PIONEER 6 (Madrid Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_504;
P3
No significant differences in outcomes could be detected between those subjects receiving metformin and those who were not. These findings indicate that the CV and metabolic benefits of semaglutide can be observed regardless of metformin use at baseline.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Effect of semaglutide 2.4 mg on glucose metabolism and body weight in adults with overweight or obesity and type 2 diabetes in the STEP 2 trial (Madrid Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_502;
P3
Weight loss with semaglutide 2.4 mg was accomplished with improvements in insulin resistance and β-cell function, two key mechanistic drivers and pathophysiologic abnormalities that cause type 2 diabetes and fuel diabetes progression. With semaglutide 2.4 mg, more patients achieved HbA1c <7.0% and weight loss ≥10% (composite endpoint) vs placebo or semaglutide 1.0 mg, and reduced oral antihyperglycaemic drug use vs placebo.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Influence of baseline characteristics on weight loss with semaglutide 2.4 mg in adults with overweight/obesity and type 2 diabetes (STEP 2) (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_480;
P3
With semaglutide 2.4 mg, more patients achieved HbA1c <7.0% and weight loss ≥10% (composite endpoint) vs placebo or semaglutide 1.0 mg, and reduced oral antihyperglycaemic drug use vs placebo. With the exception of female sex, which was associated with a greater weight loss response to semaglutide 2.4 mg, weight loss was not influenced by baseline characteristics including body weight category, HbA1c and use of non-weight neutral therapy.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Effect of semaglutide 2.4 mg on achievement of weight loss and HbA1c <7%, without hypoglycaemia, in adults with overweight/obesity and type 2 diabetes in STEP 2 (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_478;
P3
More patients on semaglutide 2.4 mg achieved clinically meaningful WL (≥5-≥20%) and glycaemic target of HbA1c <7%, without hypoglycaemia, vs semaglutide 1.0 mg and PBO. These results were more pronounced when patients were not on SUs at baseline.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
[VIRTUAL] Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight or obesity in the STEP 1 trial (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_477;
P3
These results were more pronounced when patients were not on SUs at baseline. Once-weekly semaglutide 2.4 mg allowed most adults with overweight/obesity and prediabetes to revert to normoglycaemia at week 68.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
What about wegovy? (Twitter) - Jul 11, 2021
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal: The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating and gastric emptying in subjects with obesity. (Pubmed Central) - Jul 10, 2021
In subjects with obesity, once-weekly subcutaneous semaglutide 2.4 mg suppressed appetite, improved control of eating, and reduced food cravings, ad libitum energy intake and bodyweight versus placebo. There was no evidence of delayed gastric emptying at week 20, assessed indirectly via paracetamol absorption.
- || Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal: Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). (Pubmed Central) - Jul 9, 2021
- Semaglutide was superior to liraglutide in reducing HbA and body weight. Safety profiles were generally similar, except for higher rates of gastrointestinal AEs with semaglutide vs liraglutide.
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage (clinicaltrials.gov) - Jul 9, 2021
P2, N=65, Completed, Sponsor: Novo Nordisk A/S
Safety profiles were generally similar, except for higher rates of gastrointestinal AEs with semaglutide vs liraglutide. Active, not recruiting --> Completed